AR020065A1 - Uso de inhibidores de proteasas de cisteina para la fabricacion de un medicamento y composicion farmaceutica que los comprende - Google Patents

Uso de inhibidores de proteasas de cisteina para la fabricacion de un medicamento y composicion farmaceutica que los comprende

Info

Publication number
AR020065A1
AR020065A1 ARP990101578A ARP990101578A AR020065A1 AR 020065 A1 AR020065 A1 AR 020065A1 AR P990101578 A ARP990101578 A AR P990101578A AR P990101578 A ARP990101578 A AR P990101578A AR 020065 A1 AR020065 A1 AR 020065A1
Authority
AR
Argentina
Prior art keywords
ylcarbonyl
thiazol
leucinyl
hydrazide
amino
Prior art date
Application number
ARP990101578A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR020065A1 publication Critical patent/AR020065A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Se refiere a composicion farmacéuticas que inhiben proteasas, tales como las proteasas de cisteína. En particular, se refiere al uso de inhibidores deproteasas de cisteína para la fabricacion de un medicamento para inhibir las proteasas de cisteína,que comprende un compuesto elegido entre el grupo formadopor 2-[N-(N-benciloxicarbonilglicinil)]-2-[N-benciloxicarbonil-L-leucinil)]carbohidrazida; (3RS)-1-(N-benciloxilocarbonil-L-leucinil)-3-[N(4-fenoxibenzoil)amino]pirrolidin-4-ona; (1S)-N-[2-[1-(N-benciloxicarbonilamino)-3-metilbutil]-tiazol-4-ilcarbonil]]-N-[N-(2-piridinilmetoxicarbonil)-L-leucinil]hidrazida; 1-(N-benciloxicarbonil-L-leucinilamino)-3-(2-benciloxifenilsulfonil)amino-propan-2-ona; N-[2-(2-benciloxifenil)tiazol-4-ilcarbonil]-N-[N-(3-piridinilmetoxi-carbonil)-L-leucinil]hidrazida; (1S)-N-[2-[1-(N-benciloxicarbonilamino)-3-metilbutil]-tiazol-4-ilcarbonil-N-[N(3-piridinilmetoxicarbonil)-L-leucinil]]hidrazida; 1-[N-(4-morfolinocarbamoil)-L-leucinilamino]-3-(4-fenoxifenilsulfonil)amino-propan-2-ona; N-[2-(1-naftil)tiazol-4-ilcarbonil]-N-[N-(4-piridinil-metoxicarbonil)-L-leucinil]hidrazida; N-[2-(2-benciloxifenil)tiazol-4-ilcarbonil]-N-(N-pirazinacarbonil-L-leucinil)hidrazida; N-[N-(1-bencil-5-metilimidazol-4-ilcarbonil)-L-leucinil]-N-[2-(1-naftil)tiazol-4-ilcarbonil]hidrazida; (3RS)-3-[N-(-benciloxibenzoil)-L-leucinilamino]tetrahidrofuran-4-ona; N-[2-[N-ciclopropil-N-(2-metilpropil)amino]tiazol-4-il-carbonil]-N-[N-(5-metil-2-feniloxazol-4-ilcarbonil)-L-leucinil]hidrazida; 1-[3-(2-piridinil)fenilacetamilano]-3-[N-(2-tiofenocarbonil)-L-leucinilamino]propan-2-ona; (3S)-3-[N-(benzotiazol-6-ilcrbonil)-L-leucinilamino]-1-[3-(2-piridinil)fenilacetilamino]butan-2-ona; N-[2-[N-ciclopropil-N-(2-metilpropil)amino]tiazol-4-il-carbonil]-N-[N-(7-metoxibenzofuran-2-ilcarbonil)-L-beta-ciclopropilalanil]hidrazida; 1-[N-(benzoxazol-5-ilcarbonil)-L-leucinilamino]-3-[3-2-piridinil)fenilacetilamino]propan-2-ona; 1-[N-[4-[2-(N,N-dimetilamino)etoxi]benzoil]-L-leucinilamino]-3-[3-(2-piridinil)fenilacetilamino]propan-2-ona; y N-[2-[N-ciclopropil-N-(2-metilpropil)amino)tiazol-4-il-carbonil]-N-[N-[5[2-(N,N-dimetilamino)etoxi]benzofuran-2-ilcarbonil]-
ARP990101578A 1998-04-09 1999-04-07 Uso de inhibidores de proteasas de cisteina para la fabricacion de un medicamento y composicion farmaceutica que los comprende AR020065A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8122198P 1998-04-09 1998-04-09

Publications (1)

Publication Number Publication Date
AR020065A1 true AR020065A1 (es) 2002-04-10

Family

ID=22162839

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101578A AR020065A1 (es) 1998-04-09 1999-04-07 Uso de inhibidores de proteasas de cisteina para la fabricacion de un medicamento y composicion farmaceutica que los comprende

Country Status (17)

Country Link
EP (1) EP1068304A4 (es)
JP (1) JP2002511491A (es)
KR (1) KR20010042535A (es)
CN (1) CN1304447A (es)
AR (1) AR020065A1 (es)
AU (1) AU3482099A (es)
CA (1) CA2327282A1 (es)
CO (1) CO5080800A1 (es)
DZ (1) DZ2752A1 (es)
HU (1) HUP0101513A2 (es)
IL (1) IL138628A0 (es)
MA (1) MA26618A1 (es)
NO (1) NO20005032L (es)
PE (1) PE20000421A1 (es)
PL (1) PL343373A1 (es)
TR (1) TR200002940T2 (es)
WO (1) WO1999053039A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143742A (en) * 1997-12-11 2000-11-07 Fuisz Technologies Ltd Treatment for necrotizing infections
DZ2796A1 (fr) * 1998-05-21 2003-12-01 Smithkline Beecham Corp Composés à fonction bis-aminométhyl-carbonyle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US6083966A (en) 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
EP1488791A3 (en) * 1998-09-21 2005-04-06 University Of Florida Research Foundation, Inc. Antimalarial agents
NZ509172A (en) 1998-09-21 2004-02-27 Univ Florida Antimalarial agents
CO5150165A1 (es) * 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
WO2001034599A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
WO2001034600A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
US6534498B1 (en) 1999-11-10 2003-03-18 Smithkline Beecham Corporation Protease inhibitors
AU2001243441B2 (en) 2000-03-21 2004-11-25 Smithkline Beecham Corporation Protease inhibitors
US6635784B2 (en) 2000-09-29 2003-10-21 Eastman Chemical Company Process for the preparation of enantiomerically-enriched cyclopropylalanine derivates
EP1358183B1 (en) * 2000-11-17 2006-04-12 Medivir Ab Cysteine protease inhibitors
US7132449B2 (en) 2001-01-17 2006-11-07 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
WO2002057270A1 (en) 2001-01-17 2002-07-25 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
CA2434068A1 (en) 2001-01-17 2002-07-25 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
JP2005515254A (ja) 2002-01-17 2005-05-26 スミスクライン ビーチャム コーポレーション カテプシンｋ阻害剤として有用なシクロアルキルケトアミド誘導体
US8921521B2 (en) 2003-06-18 2014-12-30 Ocera Therapeutics, Inc. Macrocyclic modulators of the Ghrelin receptor
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005034949A1 (en) 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
DK1866296T3 (en) 2005-04-04 2017-02-13 Univ Florida DESFERRITHIOCINPOLYETHER-ANALOGS
US20090264479A1 (en) * 2005-07-26 2009-10-22 Cameron Black Papain Family Cysteine Protease Inhibitors for the Treatment of Parasitic Diseases
BRPI0809077A2 (pt) 2007-03-15 2014-09-09 Univ Florida Res Foudantion Inc Análogos de poliéter de desferritiocina
ES2533875T3 (es) 2007-11-29 2015-04-15 Merck Canada Inc. Inhibidores de la cisteína proteasa para el tratamiento de enfermedades parasitarias
WO2009087379A2 (en) 2008-01-09 2009-07-16 Amura Therapeutics Limited Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases
US20140343110A1 (en) 2011-12-16 2014-11-20 University Of Florida Research Foundation, Inc. Uses of 4'-desferrithiocin analogs
EP2633855A1 (en) 2012-03-01 2013-09-04 Veterinärmedizinische Universität Wien Protease inhibitors for treating Trichomonas gallinae infections
EP3071201A4 (en) 2013-11-22 2017-04-26 University of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
CA2984250A1 (en) 2015-04-27 2016-11-03 University Of Florida Research Foundation, Incorporated Metabolically programmed metal chelators and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776718A (en) * 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
KR19990067184A (ko) * 1995-10-30 1999-08-16 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 프로테아제 억제제
DZ2285A1 (fr) * 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
MA26487A1 (fr) * 1997-04-29 2004-12-20 Smithkline Beecham Corp Heterocyclecetohydrazides inhibiteurs de proteases, procede pour leur preparation et compositions pharmaceutiques les contenant .

Also Published As

Publication number Publication date
MA26618A1 (fr) 2004-12-20
NO20005032D0 (no) 2000-10-06
CO5080800A1 (es) 2001-09-25
EP1068304A1 (en) 2001-01-17
WO1999053039A1 (en) 1999-10-21
TR200002940T2 (tr) 2001-02-21
PE20000421A1 (es) 2000-05-21
CN1304447A (zh) 2001-07-18
PL343373A1 (en) 2001-08-13
KR20010042535A (ko) 2001-05-25
EP1068304A4 (en) 2001-05-09
CA2327282A1 (en) 1999-10-21
JP2002511491A (ja) 2002-04-16
HUP0101513A2 (hu) 2001-08-28
AU3482099A (en) 1999-11-01
DZ2752A1 (fr) 2003-09-15
IL138628A0 (en) 2001-10-31
NO20005032L (no) 2000-11-16

Similar Documents

Publication Publication Date Title
AR020065A1 (es) Uso de inhibidores de proteasas de cisteina para la fabricacion de un medicamento y composicion farmaceutica que los comprende
RU2368604C2 (ru) Ингибиторы фосфодиэстеразы 4, включающие n-замещенные аналоги анилина и дифениламина
EA200200975A1 (ru) Гидрохлорид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси] бензил]тиазолидин-2,4-диона
AR054445A1 (es) Formulaciones de un inhibidor de src/abl
RS51343B (sr) Nova kompozicija i njena upotreba
AR051965A1 (es) Sales de la n-[2-( { (3r)-1-[trans-4-hidroxi-4-(6- metoxipiridin-3-il)-ciclohexil] pirrolidin-3- il} amino)-2- oxoetil]-3-(trifluormetil) benzamida
EA200702238A1 (ru) Комбинация, способ и композиция для лечения рака
YU7998A (sh) Heterociklična jedinjenja i njihove farmaceutske kompozicije
DE69816280D1 (de) Inhibitoren des impdh-enzyms
PE20071184A1 (es) Compuestos de aminoisoindolina para el tratamiento del lupus cutaneo
EA200501805A1 (ru) Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
NO20091892L (no) Krystallinsk form av (3S)-3-(N-(N`-(2-tert-butylfenyl)oksamyl) alaninyl)amino-5-(2`,3`,5`,6`-tetrafluorfenoksy)-4 oksopentanoisk syre
MXPA03010054A (es) Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
MXPA04001364A (es) Uso de bibn4096 en combinacion con otros farmacos anti-migrana para el tratamiento de migrana, composicion y equipo.
AR014270A1 (es) Sustancia inhibidora de metaloproteasas de matriz, composicion farmaceutica, uso en la fabricacion de medicamentos, procedimiento parafabricarla y compuestos intermediarios
PE20050440A1 (es) Derivados de n-heterociclo sustituidos para modificar la recaptacion de monoaminas
WO2006114702A3 (en) Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
DE60103284D1 (de) Antifungizide zusammensetzung von ketoconazole zum auftragen
RU2003115431A (ru) Новые применения объединенных агонистов 5-нт1а и ингибиторов обратного захвата серотонина
TW200501956A (en) Use of the hydrochloride of the compound 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine in combination with sumatriptan for the treatment of migraine
NO20042871L (no) Sitronsyre-salt av en terapeutisk forbindelse og farmasoytiske blandinger derav
HUP0001591A2 (hu) Metalaxilt és dimetomorfot tartalmazó fungicid készítmény és alkalmazása
RU2003116893A (ru) Новое применение объединенных агонистов 5-нт1а и ингибиторов обратного захвата серотонина
DE59303446D1 (de) Neue bis-phenyl-hexene
Kim et al. (4-Piperidinylphenyl) aminoethyl amides as a novel class of non-covalent cathepsin K inhibitors